Current landscape of innovative drug development and regulatory support in China
Abstract The global pharmaceutical landscape remains dynamic and competitive, shaped by advancements in first-in-class therapies and breakthrough technologies. The United States has maintained its leadership in first-in-class therapies and breakthrough technologies, driven by advanced regulatory pat...
Saved in:
| Main Authors: | Ruirong Tan, Hua Hua, Siyuan Zhou, Zhimin Yang, Changming Yang, Guo Huang, Jin Zeng, Junning Zhao |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2025-07-01
|
| Series: | Signal Transduction and Targeted Therapy |
| Online Access: | https://doi.org/10.1038/s41392-025-02267-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Overview of pharmacodynamical research of traditional Chinese medicine on hyperuricemic nephropathy: from the perspective of dual-regulatory effect on the intestines and kidneys
by: Ting Wang, et al.
Published: (2025-04-01) -
Landscape of regulatory quantitative systems pharmacology submissions to the U.S. Food and Drug Administration: An update report
by: Jane P. F. Bai, et al.
Published: (2024-12-01) -
Regulatory and clinical outcomes of priority-reviewed innovative cancer drugs in China between 2015 and 2024: an observational study
by: Qi Li, et al.
Published: (2025-07-01) -
Current Landscape of Temporary Percutaneous Mechanical Circulatory Support Technology
by: Rani Upadhyay, et al.
Published: (2021-11-01) -
The current landscape and future direction of curriculum reform in China
by: Shengquan Luo
Published: (2023-09-01)